Contineum reports Q3 2024 cash $213.9M, VISTA trial enrollment on track

Contineum Therapeutics, Inc.

2024-Q3 EPS reported -$1.61

Cash, equivalents and marketable securities $213.9M as of Sept 30, 2024 (vs $125.2M at end of 2023).
R&D expense $9.7M (+$3.2M YoY) driven by VISTA Phase 2 trial and PIPE-791 toxicology studies.
VISTA trial for PIPE-307 in RRMS two-thirds enrolled; full enrollment expected first half 2025.
Pending MHRA authorization, Phase 1b PET trial for PIPE-791 to start Dec 2024 with data in H1 2025.
Janssen confirms on track to initiate Phase 2 trial of PIPE-307 in depression.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.